Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Histone deacetylase 8 (HDAC8)

In vitro studies identified an HDAC8-selective inhibitor that could help treat cancer. In vitro screening identified a hydroxamate-based molecule that inhibited HDAC8 with an IC50 of 70 nM and showed selectivity over other HDAC isoforms. In a panel of human T cell lymphoma and neuroblastoma cell lines, the inhibitor blocked proliferation at low- to mid-micromolar concentrations. Next steps include testing the HDAC8-selective inhibitors in mouse xenograft models of cancer.
Pharmacyclics Inc. has the HDAC8 inhibitor PCI-34051 in preclinical development for various cancers.
TeraDiscoveries Inc. has the HDAC8 inhibitor TA-H8 in preclinical development for T cell lymphoma.

SciBX 5(47); doi:10.1038/scibx.2012.1231
Published online Dec. 6, 2012

Patent application filed; available for licensing

Suzuki, T. et al. J. Med. Chem.; published online Nov. 1, 2012;
doi:10.1021/jm300837y
Contact: Naoki Miyata, Nagoya City University, Aichi, Japan
e-mail:

miyata-n@phar.nagoya-cu.ac.jp
Contact: Takayoshi Suzuki, Kyoto Prefectural University of Medicine, Kyoto, Japan
e-mail:

suzukit@koto.kpu-m.ac.jp